Beneath Lululemon’s Stock Slump Lies a Broader Spending Squeeze
Lululemon shares have plunged 53% in 2026, but Michael Burry sees opportunity as weakness spreads across apparel, retail and the broader consumer sector.
Stocks · News reference
Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Will Howie Buffett Keep Berkshire Ahead of the S&P 500? What Retail Investors Need to Know
Warren Buffett is out. As Howie Buffett takes over Berkshire Hathaway, can BRK.B still beat the S&P 500? What retail investors need to know.
Home Depot vs. Spotify Technology: Which Consumer Stock Is a Better Buy in 2026?
The article compares Home Depot and Spotify Technology as investment options for 2026. Home Depot, the dominant home improvement retailer, offers steady returns and a 3.07% dividend yield but faces headwinds from a sluggish housing market. Spotify, the global audio streaming leader, demonstrates faster revenue growth (9.7%), record gross margins (32.7%), and improved profitability, making it the author's preferred choice for long-term investors seeking growth exposure.
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.
Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million in damages plus
8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than